Skip to Content

Chugai Pharmaceutical Co Ltd ADR CHGCY Stock Quote

| Rating as of


Last close prices updated as of May 30, 2023, 3:59 PM EST | USD
  • Last Close 13.56
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 13.53  –  13.63
  • Year Range 10.99  –  14.86
  • Market Cap 44.5939 Bil
  • Volume / Avg 98,655.0 /  83,029.6
  • Price / Sales 5.10
  • Price / Book 4.29
  • Forward Div Yield 2.13%
  • Trailing Div Yield 2.12%

Morningstar‘s Stock Analysis CHGCY

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CHGCY

Company Profile CHGCY

Business Description

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several notable therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku
Tokyo, 103-8324, JPN
Industry Drug Manufacturers - General
Employees 7,664

Competitors & Peers CHGCY

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of CHGCY’s competitive advantage.

Chugai Pharmaceutical Co Ltd ADR


Takeda Pharmaceutical Co Ltd

XTKS: 4502
+$0.09 (0.67%) +$3.00 (0.07%)
Market Cap
44.59 Bil7.06 Tril
Drug Manufacturers - General Drug Manufacturers - Specialty & Generic

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Chugai Pharmaceutical Co Ltd ADR Stock

Yes. CHGCY has a forward dividend yield of 2.13%. See CHGCY’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CHGCY’s market cap is 44.59 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CHGCY’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CHGCY’s price/sales is 4.95.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

CHGCY’s price/forward earnings is 18.98.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

CHGCY’s price/book is 4.11.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See CHGCY’s valuation ratios compared to the Market Index.

CHGCY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CHGCY’s historical performance against its industry peers and the overall market.